Premium
National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral‐naïve patients
Author(s) -
Hart E,
Curtis H,
Wilkins E,
Johnson M
Publication year - 2007
Publication title -
hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 79
eISSN - 1468-1293
pISSN - 1464-2662
DOI - 10.1111/j.1468-1293.2007.00451.x
Subject(s) - medicine , regimen , antiretroviral therapy , human immunodeficiency virus (hiv) , drug holiday , audit , antiretroviral treatment , intensive care medicine , viral load , pediatrics , family medicine , management , economics
Objectives The aim of the study was to explore the factors surrounding modification of the first antiretroviral (ARV) regimen where drug switch occurred 3 months or more after initiation. Reference was made to the British HIV Association (BHIVA) guidelines on HIV management. Methods A case note and questionnaire‐based audit was carried out. Results Toxicity was the single most important reason for ARV change and was the only, or a contributory, cause in over half the patients. Virological failure, adherence issues, requirement for treatment simplification, and patient request were other significant reasons cited. In one‐third of those with virological failure, six or more months had elapsed between first detection and the time of switching to a new ARV regimen. Conclusions This audit demonstrated broad adherence to the BHIVA guidelines, although the long time before switching ARVs in the setting of virological failure was of some concern, particularly given the continuing and significant occurrence of primary ARV resistance in the UK.